Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 22, 2007

ProMetic and Tecpar Sign $19M Technology Transfer and Licensing Transaction

  • In a $19-million transaction with ProMetic Life Sciences, Tecpar will locally manufacture a biopharmaceutical product for the Brazilian domestic market as well as all other South American countries.

    ProMetic will manage the development of the proprietary manufacturing process that is based on technology licensed from the Biotechnology Research Institute (BRI) and the company’s own bioseparation process, which uses Mimetic Ligand™ technology.

    As part of the technology transfer and licensing agreement, ProMetic has granted Tecpar exclusive rights to use the technology for the selected biopharmaceutical product. The project will involve a selected team from all parties, including scientists and engineers from ProMetic, BRI, Tecpar as well as Validapro, a Quebec-based company dedicated to fulfilling regulatory compliance needs in the pharmaceutical industry.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »